#VisualAbstract: Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis
1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain ...
1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain ...
1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.